决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
100.0分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于间充质干细胞的胶质瘤治疗
英文原题：Mesenchymal-Stem-Cell-Based Therapy against Gliomas.
查看英文原题
Mesenchymal-Stem-Cell-Based Therapy against Gliomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤是中枢神经系统中侵袭性最强、恶性程度最高且致死性最高的脑肿瘤。其预后不佳源于对当前治疗（包括手术切除、放疗和化疗）应答效率低下。近期，间充质干细胞（MSC）因具有免疫调节特性、肿瘤趋向性且能够分化为其他细胞类型，作为胶质母细胞瘤潜在细胞疗法受到广泛关注。然而，MSC的抗肿瘤或促肿瘤作用似乎取决于其来源组织。本文介绍利用MSC递送治疗基因、溶瘤病毒和miRNA的可能性，以及增强其抗胶质母细胞瘤疗效的策略，例如结合CAR-T 细胞、纳米颗粒和外泌体。
展开英文摘要原文
Glioblastoma is the most aggressive, malignant, and lethal brain tumor of the central nervous system. Its poor prognosis lies in its inefficient response to currently available treatments that consist of surgical resection, radiotherapy, and chemotherapy. Recently, the use of mesenchymal stem cells (MSCs) as a possible kind of cell therapy against glioblastoma is gaining great interest due to their immunomodulatory properties, tumor tropism, and differentiation into other cell types.
However, MSCs seem to present both antitumor and pro-tumor properties depending on the tissue from which they come. In this work, the possibility of using MSCs to deliver therapeutic genes, oncolytic viruses, and miRNA is presented, as well as strategies that can improve their therapeutic efficacy against glioblastoma, such as CAR-T cells, nanoparticles, and exosomes.
论文信息
- 作者
- Santillán-Guaján SM、Shahi MH、Castresana JS
- 单位
- Department of Biochemistry and Genetics, University of Navarra School of Sciences, 31008 Pamplona, Spain.Spain
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cells2024 Apr 2
- 原文标识
- PubMed 38607056 · DOI 10.3390/cells13070617